Colloid Cancer: Complexity of Diagnosis, Problems and Solutions (a clinical case)

DOI: 10.47026/2413-4864-2024-3-71-80

UDC: 616.33-006.6-07
BBC: Р569.433-4

Efimova O.A., Diomidova V.N., Zhuravleva N.V., Orlova S.A., Guryanova E.A., Pushkina N.S.

Colloid Cancer: Complexity of Diagnosis, Problems and Solutions (a clinical case)

Keywords: stomach, colloid cancer, histomorphological examination, ultrasound examination, computed tomography, surgical treatment

Colloid cancer of the stomach has a worse prognosis and lower chemo-sensitivity than other forms of stomach cancer. Characteristic of this stomach tumor is low detectability of the tumor at an early stage and pronounced invasiveness with rapid progression of the tumor process. The article presents a clinical case of late diagnosis of colloid stomach cancer in a 59-year-old patient. The patient was examined according to the National Clinical Guidelines for Gastric Cancer. A complex use of various methods for gastric examination in the diagnosis of an advanced clinical case of colloid cancer of the stomach showed the predominant informative value of radiation diagnostic methods in contrast to esophagogastroduodenoscopy. At this, the results of ultrasound and computed tomography examinations of the stomach were comparable and fully confirmed by the results of surgical intervention. Histomorphological examination data verified colloid cancer of the stomach.

References

Klinicheskie rekomendatsii “Rak zheludka” [Clinical Guidelines “Stomach Cancer”]. All-Russian National Union “Association of Oncology of Russia” and All-Russian Public Organization “Russian Society of Clinical Oncology”, Moscow, 2020, 95 p.
Al-Batran S.-E., Hofheinz R., Scmalenberg H., Strunberg D. Perioperative ramucirumab in combination with FLOT versus FLOT alone for resectable esophagogastric adenocarcinoma (RAMSES/FLOT7): Results of the phase II-portion – A multicenter, randomized phase II/III trial of the German AIO and Italian GOIM. Journal of Clinical Oncology, 2020, vol. 38(15), p. 4501. DOI:10.1200/JCO.2020.38.15.
Chang C., Sun C., Pai H. et al. Preoperative serum C-reactive protein and gastric cancer; clinical-pathological correlation and prognostic significance. Chang Gung Med J., 2010, vol. 33(3), pp. 301–312. PMID: 20584508.
Chung K., Muthutantri A., Goldsmith G. et al. Symptom impact and health-related quality of life (HRQoL) assessment by cancer stage: a narrative literature review. BMC Cancer, 2024, vol. 24(1), p. 884. DOI: 10.1186/s12885-024-12612-z.
Correa P. Gastric cancer: overview. Gastroenterol Clin North Am, 2013, vol. 7(2), pp. 211–217. DOI: 10.1016/j.gtc.2013.01.002.
Cunningham D., Stenning S., Smyth E. et al. Perioperative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. Lancet Oncol, 2017, vol. 18(3), pp. 357–370. DOI: 10.1016/S1470-2045(17)30043-8.
Drubay V., Nuytens F., Renaud F. et al. Poorly cohesive cells gastric carcinoma including signet-ring cell cancer: Updated review of definition, classification and therapeutic management.World J Gastrointest Oncol, 2022, vol. 14(8), pp. 1406–1428. DOI: 10.4251/wjgo.v14.i8.1406.
Franko J., Le V., Tee M. et al. Signet ring cell carcinoma of the gastrointestinal tract: National trends on treatment effects and prognostic outcomes. Cancer Treat Res Commun, 2021, vol. 29. DOI: 10.1016/j.ctarc.2021.100475.
Gholami S., Cassidy M., Strong V. Minimally Invasive Surgical Approaches to Gastric Resection. Surg Clin North Am, 2017, vol. 97(2), pp. 249–264. DOI: 10.1016/j.suc.2016.11.003.
Guan W., He Y., Xu R. Gastric cancer treatment: recent progress and future perspectives. JHematol Oncol, 2023, vol. 16(1), p. 57. DOI: 10.1186/s13045-023-01451-3.
Heger U., Blank S., Wiecha C. et al. Is pre‑operative chemot. herapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Annals of Surgical Oncology, 2014, vol. 21(5), pp. 1739–1748. DOI: 10.1245/s10434-013-3462-z.
Krieg S., Loosen S., Krieg A., Luedde T. et al. Association between iron deficiency anemia and subsequent stomach and colorectal cancer diagnosis in Germany. J Cancer Res Clin Oncol., 2024, vol. 150(2), p. 53. DOI: 10.1007/s00432-023-05534-z.
Machlowska J., Pucułek M., Sitarz M. et al. State of the art for gastric signet ring cell carcinoma: from classification, prognosis, and genomic characteristics to specified treatments. Cancer Manag Res, 2019, vol. 11, pp. 2151–2161. DOI: 10.2147/CMAR.S188622.
Majeed W., Iftikhar A., Khaliq T. et al. Gastric Carcinoma: Recent Trends in Diagnostic Biomarkers and Molecular Targeted Therapies. Asian Pac J Cancer Prev, 2016, vol. 17(7), pp. 3053–3060. PMID: 27509928.
Martin A., Das D., Turrentine F., Bauer T. et al. Morbidity and Mortality After Gastrectomy: Identification of Modifiable Risk Factors. Journal of Gastrointestinal Surgery, 2016, vol. 20(9), pp. 1554–1564. DOI: 10.1007/s11605-016-3195-y.
Ohyama H., Yoshimura D., Hirotsu Y. et al. Rapidly declining trend of signet ring cell cancer of the stomach may parallel the infection rate of Helicobacter pylori. BMC Gastroenterol, 2019, vol. 19(1), p. 178. DOI: 10.1186/s12876-019-1094-x.
Patel R., Baer J., Texeira J. et al. Internal hernia complications of gastric bypass surgery in the acute setting: spectrum of imaging findings. Emergency Radiology, 2009, vol. 16(4), pp. 283–289. DOI: 10.1007/s10140-008-0781-7.
Pernot S., Voron T., Perkins G. et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. World J Gastroenterol, 2015, vol. 21(40), pp. 11428–11438. DOI: 10.3748/wjg.v21.i40.11428.
Smyth E., Nilsson M., Grabsch H. et al. Gastric cancer. Lancet, 2020, vol. 396(13), pp. 635–648. DOI: 10.1016/S0140-6736(20)31288-5.
Su P., Jiang L., Zhang Y. et al. Perioperative chemotherapy versus adjuvant chemotherapy treatment for resectable locally advanced gastric cancer: a retrospective cohort study. Eur J Med Res, 2023, vol. 28(1), p. 409. DOI: 10.1186/s40001-023-01400-3.
Tabouret T., Dhooge M., Rouquette A. et al. Adénocarcinome gastrique à cellules indépendantes: une entité à part Gastric signet ring cell adenocarcinoma: A distinct entity. Presse Med, 2014, vol. 43(4), pp. 353–357. DOI: 10.1016/j.lpm.2013.07.024.
Wagner A., Grabsch H., Mauer M. et al. EORTC-1203-GITCG – the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 2019, vol. 19(1), p. 494. DOI: 10.1186/s12885-019-5675-4.
Waldum H., Fossmark R. Types of Gastric Carcinomas. Int J Mol Sci., 2018, vol. 19(12), p. 4109. DOI: 10.3390/ijms19124109.
Xu Z., Jin Y., Fang X. Advances in the research of gastric signet ring cell carcinoma. Zhonghua Wei Chang Wai Ke Za Zhi, 2018 vol. 21(10), pp. 1196–1200. PMID: 30370520.
Yang W., Zhao H., Yu Y. et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol,2023, vol. 29(16), pp. 2452–2468. DOI: 10.3748/wjg.v29.i16.2452.
Zhai Y., Zheng Z., Deng W. et al. Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn’t affect outcome: A meta analysis. Front Surg., 2023, vol. 9. DOI: 10.3389/fsurg.2022.1047456.
Zhang C., Liu R., Zhang W., Chen X. et al. Difference Between Signet Ring Cell Gastric Cancers and Non-Signet Ring Cell Gastric Cancers: A Systematic Review and Meta-Analysis. Oncol., 2021, vol. 11. DOI: 10.3389/fonc.2021.618477.

About authors

Efimova Oksana A.: Radiologist, Republican Oncology Dispensary; Senior Lecturer,
Department of Propaedeutics of Internal Diseases with a Course of Radiation Diagnostics, Chuvash State University, Russia, Cheboksary (oksanalekseevna.e@gmail.com; ORCID: https://orcid.org/0000-0002-0624-4992)

Diomidova Valentina N.: Doctor of Medical Sciences, Professor, Head of the Department of Propaedeutics of Internal Diseases with a Course of Radiation Diagnostics, Chuvash State University; Head of the Department of Ultrasound Diagnostics, City Clinical Hospital № 1, Russia, Cheboksary (diomidovavn@rambler.ru; ORCID: https://orcid.org/0000-0002-3627-7971)

Zhuravleva Nadezhda V.: Candidate of Medical Sciences, Associate Professor, Department of Internal Diseases, Chuvash State University; Rheumatologist, Central City Hospital, Russia, Cheboksary (zhuravlevanv@mail.ru; ORCID: https://orcid.org/0000-0001-6470-7724)

Orlova Svetlana A.: Head of the Department of Antitumor Drug Therapy, Republican Clinical Oncology Dispensary, Russia, Cheboksary (lana.orlova_84@mail.ru; ORCID: https://orcid.org/0000-0003-4618-5832)

Guryanova Evgeniya A.: Doctor of Medical Sciences, Professor, Rector, Postgraduate Doctors' Training Institute, Russia, Cheboksary (z-guryanova@bk.ru; ORCID: https://orcid.org/0000-0003-1519-2319)

Pushkina Natalia S.: Resident, Medical Faculty, Chuvash State University, Russia, Cheboksary (985natalia8845@mail.ru; ORCID: https://orcid.org/0009-0009-6517-4259)

Article link

Efimova O.A., Diomidova V.N., Zhuravleva N.V., Orlova S.A., Guryanova E.A., Pushkina N.S. Colloid Cancer: Complexity of Diagnosis, Problems and Solutions (a clinical case) [Electronic resource] // Acta medica Eurasica. – 2024. – №3. P. 71-80. – URL: https://acta-medica-eurasica.ru/en/single/2024/3/8/. DOI: 10.47026/2413-4864-2024-3-71-80.

Single article

Efimova O.A., Diomidova V.N., Zhuravleva N.V., Orlova S.A., Guryanova E.A., Pushkina N.S.